Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTX's fall is bolstering traditional risk assets

Mon, 14th Nov 2022 11:41

STOXX 600 up 0.15%

*

Informa leads media stocks up

*

Fed's Waller warns on inflation

*

U.S. stock futures dip

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at . FTX'S FALL IS BOLSTERING TRADITIONAL RISK ASSETS (1140 GMT) After the spectacular collapse of crypto exchange FTX, investors briefly worried of contagion to broader financial markets, but it was quickly established that traders now preferred the more conventional, regulated world of stock markets for high returns. "Traders prefer cutting exposure to cryptocurrencies," said Swissquote Bank's senior analyst Ipek Ozkardeskaya. She said some blame the lack of regulation for the fall of FTX and others say this kind of thing is very common in the crypto world.

As ugly as the situation remains for cryptocurrencies, analysts now argue that it has pulled focus back to stocks, especially for technology shares, which have typically been high performers.

"This means investors who might have formerly gone to Voyager or Genesis to invest in crypto assets will now instead go to the NASDAQ," said Stefan Rust, chief executive office of Laguna Labs.

Now that U.S. inflation showed some signs of cooling in October, "bottom fishing" will be the way to go for investors to capture the most upside, according to Rust.

Analysts at Citi note that cryptocurrency markets are too small and too siloed to cause contagion in the broader financial markets, "with an $890 billion market cap in comparison to U.S. equity's $41 trillion."

"FADE OR CHASE": THAT IS THE QUESTION (1117 GMT)

A number of top equity benchmarks from the DAX to the Dow are now up near 20% from October lows. A big bounce which has now investors wondering whether it should be faded or chased.

Here's how Berenberg sees it.

"Against the backdrop of a tough year for equities, these gains have been most welcome. However, the key question for investors is whether this is another bear market rally or whether this is the start of a new equity bull market?," write the German bank's strategists led by Jonathan Stubbs.

"Ahead of likely recessions across Western economies in 2023, with technical tailwinds now headwinds, and with many of our macro and fundamental signals suggesting that it is too early to turn bullish, we think that this is still a bear market rally and that investors should choose 'fade' over 'chase'," Stubbs and team add.

CREDIT WHERE CREDIT'S DUE (0958 GMT)

European investors may be breathing a sigh of relief that energy prices have come off their 2022 highs and earnings season so far is decent. But analysts believe recession is a near-certainty and the credit market shows corporate defaults are going to come in thick and fast, according to Goldman Sachs. The iTraxx Europe Crossover, an index of junk bonds , suggests annual default rates of 7-9% in European high-yield debt, compared with an average of 1-5% since 2010, Goldman said. The index is currently around 460 basis points, its lowest since August, compared with around 96.85 bps for the iTraxx Europe investment grade index .

The annualised default rate only got above 7% in the early 2000s and the great financial crisis, the bank said. While the high-yield market looks precarious, investment grade appears a better bet. "We think European credit screens as a very attractive long, stand-alone and cross-asset-wise," Goldman said in a note to clients.

PHARMA DELIVERS HEALTHY START TO THE DAY (0847 GMT)

European shares have opened in the green, with the DAX hitting its highest in five months thanks to hefty gains in the pharma sector, where Merck KGaA is leading the charge, with a 5% rally. Rivals Novo Nordisk and AstraZeneca are topping the STOXX 600 leaderboard on a weighted basis, rising 1.9% and 1.5%, respectively, while at the other end of the spectrum is Switzerland's Roche, which is down 4.7% in its largest one-day drop in six months. The company said its Alzheimer's drug candidate could not clearly be shown to slow the progression of dementia. The STOXX 600 is up around 0.3%.

On the flipside, media stocks are the best performers on a sectoral basis, with the STOXX 600 Media index up 1.2% thanks to London-listed events organiser Informa roaring as much as 8.8% higher after raising its fiscal year outlook, while miners are up 0.5% following a jump in iron ore prices after China lay out more measures to help its struggling real estate sector.

DON'T GET CARRIED AWAY (0818 GMT)

Markets have got all excited after last week's rip-roaring rally in global equities, a big tumble in U.S. Treasury yields and a bruising sell-off in the mighty dollar.

But don't pop the champagne just yet.

Federal Reserve Gov. Christopher Waller said on Sunday that the Fed may consider slowing the pace of rate increases at its next meeting but that should not be seen as a "softening" of its battle against inflation.

While U.S. consumer prices rose less than expected in October, pushing the annual increase below 8% for the first time in eight months, Waller said the markets shouldn't get carried away over just one "data point."

The comments tempered gains in Asian equity markets on Monday, though Hong Kong and Chinese stocks outperformed as China fine-tuned COVID-19 control measures and regulators ordered more financing support for the beleaguered real estate sector.

And days before the announcement of a budget plan, British Finance Minister Jeremy Hunt said he will set out tax rises and spending cuts to show Britain can fix its public finances and restore its economic credibility.

At least the sporting world brought good news for England after Captain Ben Stokes held his nerve with an unbeaten half-century on Sunday, helping England claim their second Twenty20 World Cup title with a five-wicket win over Pakistan.

This week, U.S. retail sales will dominate the data calendar, while markets will also pay attention to euro zone flash Q3 GDP estimates.

As the G20 summit kicks off in the Indonesian island of Bali on Tuesday, U.S. President Joe Biden is set to meet Chinese leader Xi Jinping in person for the first time since taking office, with U.S. concerns over Taiwan, Russia's war in Ukraine and North Korea's nuclear ambitions on top of his agenda.

In the crypto world, after Friday's shocking collapse of cryptocurrency exchange FTX, Bahamas authorities said they were scrutinising the demise of the exchange, co-founded by 30-year-old Sam Bankman-Fried.

And finally, on the European corporate front, German military equipment manufacturer Rheinmetall agreed to acquire Spanish explosives and ammunition maker Expal Systems for an enterprise value of 1.2 billion euros.

Key developments that could influence markets on Monday:

Economic data: Euro zone Sep inflation final

Biden-Xi meeting

G20 leaders summit to Nov. 16th

Biden-Xi meeting

Fed's Brainard speaks

EUROPE CAUTIOUSLY OPTIMISTIC (0735 GMT)

European stock index futures are pointing to a modestly higher start today, but the mood is a lot more cautious. Last week's U.S. inflation data for October unleashed the biggest weekly rally in global stocks in two years, but the party might not last long. Fed Reserve Governor Christopher Waller said on Sunday that it was "just one data point" and the central bank is going to need a lot more where that came from to be convinced to take its foot off the gas. After an upbeat session for equities in Asia, where China has relaxed some of its tough COVID restrictions, STOXX 50 futures are up 0.4%, while FTSE futures are 0.2% higher and DAX futures are up 0.3%.

Traders see Roche opening as much as 5% lower after the Swiss pharma group said its Alzheimer's drug candidate could not clearly be shown to slow dementia progression, while miners look to make some headway after a jump in iron ore prices after China laid out some support measures for the struggling real-estate sector. UK-listed events organiser Informa looks set to gain after upbeat results.

More News
Today 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.